News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
800,215 Results
Type
Article (73461)
Company Profile (693)
Press Release (726061)
Section
Business (227029)
Career Advice (3693)
Deals (39230)
Drug Delivery (113)
Drug Development (89003)
Employer Resources (194)
FDA (17726)
Job Trends (17068)
News (386855)
Policy (38643)
Tag
Academia (2974)
Alliances (55556)
Alzheimer's disease (1323)
Approvals (17621)
Artificial intelligence (137)
Bankruptcy (392)
Best Places to Work (12448)
Biotechnology (474)
Breast cancer (116)
Cancer (983)
Cardiovascular disease (90)
Career advice (3144)
Cell therapy (224)
Clinical research (70016)
Collaboration (351)
Compensation (174)
COVID-19 (2794)
Data (875)
Diabetes (148)
Diagnostics (6632)
Drug pricing (100)
Earnings (91299)
Employer resources (167)
Events (124961)
Executive appointments (256)
FDA (18190)
Funding (307)
Gene therapy (169)
GLP-1 (673)
Government (4988)
Healthcare (20684)
Infectious disease (2875)
Inflammatory bowel disease (115)
Interviews (721)
IPO (17492)
Job creations (4981)
Job search strategy (2585)
Layoffs (482)
Legal (9838)
Lung cancer (171)
Manufacturing (173)
Medical device (14371)
Medtech (14376)
Mergers & acquisitions (21725)
Metabolic disorders (423)
Neuroscience (1590)
NextGen Class of 2024 (7613)
Non-profit (5060)
Northern California (1234)
Obesity (250)
Opinion (241)
Patents (103)
People (62812)
Pharmaceutical (137)
Phase I (21555)
Phase II (30533)
Phase III (23063)
Pipeline (212)
Postmarket research (3243)
Preclinical (9520)
Radiopharmaceuticals (256)
Rare diseases (202)
Real estate (7125)
Regulatory (25147)
Research institute (2639)
Resumes & cover letters (578)
Southern California (1111)
Startups (4181)
United States (12590)
Vaccines (638)
Weight loss (208)
Date
Today (171)
Last 7 days (850)
Last 30 days (3005)
Last 365 days (38434)
2024 (32655)
2023 (42565)
2022 (53926)
2021 (58725)
2020 (57668)
2019 (51305)
2018 (39085)
2017 (36832)
2016 (37740)
2015 (43731)
2014 (38413)
2013 (34389)
2012 (36287)
2011 (36404)
2010 (35835)
Location
Africa (1186)
Arizona (201)
Asia (47751)
Australia (8209)
California (2909)
Canada (1188)
China (220)
Colorado (128)
Connecticut (136)
Europe (107610)
Florida (406)
Georgia (109)
Illinois (369)
Indiana (195)
Kansas (101)
Maryland (564)
Massachusetts (2429)
Michigan (160)
Minnesota (271)
New Jersey (869)
New York (868)
North Carolina (789)
Northern California (1234)
Ohio (133)
Pennsylvania (762)
South America (1560)
Southern California (1111)
Texas (417)
Washington State (357)
800,215 Results for "takeda pharmaceutical co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
JCR Pharmaceuticals Co., Ltd. announced today that Takeda Pharmaceutical Co., Ltd. (“Takeda”) decided to discontinue their collaboration with JCR to develop gene therapies using adeno-associated viruses (AAV) combined with the JCR J-Brain Cargo ® Technology.
December 21, 2023
·
4 min read
Huntington’s disease
Takeda Walks Away From Wave Huntington’s Partnership After Sinking $260M in Collaboration
Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on Wave’s WVE-003 clinical-stage Huntington’s disease program—a potential $5 billion commercial opportunity, according to the biotech.
October 16, 2024
·
3 min read
·
Tristan Manalac
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
Drug Development
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.
May 28, 2024
·
2 min read
BioMidwest
AriBio Co., Ltd. Announces Strategic Collaboration with Kentucky Clinical Trial Laboratory (KCTL) to Expand Alzheimer’s Disease Testing
AriBio Co., Ltd. announces the expansion of testing for Alzheimer’s disease by entering into a strategic collaboration with Kentucky Clinical Trial Laboratory for the testing of cerebral spinal fluid to accurately and efficiently aid in the diagnosis of Alzheimer’s disease using the Lumipulse® system from FujireBio.
June 21, 2024
·
3 min read
Press Releases
SEED Therapeutics Appoints Eisai Co., Ltd.’s Dr. Yoshiharu Mizui to Board of Directors
September 12, 2024
·
2 min read
Drug Development
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
Ovid Therapeutics Inc., a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, reports that Takeda Pharmaceutical Company Limited has announced topline data from its Phase 3 SKYLINE and SKYWAY studies evaluating soticlestat for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.
June 17, 2024
·
12 min read
Job Trends
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) has received notification from the European Commission (“EC”) that it has approved FRUZAQLA®.
June 21, 2024
·
17 min read
Business
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
NRx Pharmaceuticals, Inc. today announced that its Asia Pacific strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified enrollment completion of the NRx clinical trial in bipolar depression as a material event in is February 7 financial filing.
February 9, 2024
·
3 min read
1 of 80,022
Next